July 9, 2003 Richard Labaudiniere, PhD. Sherborn, MA 01770Genome Therapeutics Corp • November 12th, 2003 • In vitro & in vivo diagnostic substances
We have mutually agreed that, due to a strategic shift which will result in a discontinuation of discovery research, it is appropriate for there to be a transition and a termination of your employment with Genome Therapeutics Corp. (the “Company”) no later than December 31, 2003. The purpose of this letter is to confirm the agreement between you and the Company concerning the remainder of your employment and your separation arrangements, as follows:
